Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest MicroRNA Stories

2014-03-05 08:28:56

- Study Designed to Demonstrate Human Proof-of-Concept Results by YE 2014 - LA JOLLA, Calif., March 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has commenced dosing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122") in healthy volunteer subjects in a Phase I clinical study. The primary objective of the study...

2014-03-04 16:03:43

Researchers at New York University and the University of Texas at Austin have discovered that carbohydrates serve as identifiers for cancer cells. Their findings, which appear in the journal Proceedings of the National Academy of Sciences, show how these molecules may serve as signals for cancer and explain what's going on inside these cells, pointing to new ways in which sugars function as a looking glass into the workings of their underlying structures. "Carbohydrates can tell us a lot...

Fragile X Syndrome
2014-02-28 13:24:30

Brett Smith for redOrbit.com - Your Universe Online New research from a team of American researchers has found a genetic mechanism that shuts off the gene associated with fragile X syndrome – which causes developmental disorders such as mental retardation and autism. According to the team’s report in the journal Science, they were successfully able to a test drug that blocks this blocking mechanism. While it has been known that the syndrome is driven by the excessive repetition...

2014-02-27 16:28:10

- Achieved All Goals on 'Road to the Clinic'; Launched 'Clinical Map Initiative'- LA JOLLA, Calif., Feb. 27, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its corporate strategy and reported financial results for the fourth quarter and year ended December 31, 2013, including a summary of recent corporate highlights. Corporate Strategy...

2014-02-26 16:29:07

LA JOLLA, Calif., Feb. 26, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the Cowen and Company 34(th) Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:40 am EST. The conference is being held at the Boston...

2014-02-24 12:27:26

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Arcturus Therapeutics, Inc., a leading RNA medicines company pursuing rare diseases, today announced it will present at BIOCOM's Global Life Science Partnering Conference being held on February 26 and 27, 2014 at the Lodge in Torrey Pines, La Jolla, California. In addition to providing an update on its flagship program targeting transthyretin (TTR)-mediated amyloidosis, Arcturus will present data for its proprietary LUNAR(TM) delivery...

2014-02-20 16:25:50

LA JOLLA, Calif., Feb. 20, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2013 on Thursday, February 27, 2014, after the U.S. financial markets close. Regulus will host a conference call and webcast on Thursday, February 27, 2014 at 5:00 pm...

2014-02-19 08:31:20

-RG-012 is an anti-miR Targeting microRNA-21 for the Treatment of Alport Syndrome, a Life-Threatening, Genetic Kidney Disease with No Approved Therapy- LA JOLLA, Calif., Feb. 19, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has advanced its orphan disease portfolio with the nomination of its second microRNA candidate for clinical...

2014-02-13 08:30:40

-Martin Beaulieu, Ph.D. Brings Extensive Diagnostic Assay Development Experience- LA JOLLA, Calif., Feb. 13, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Martin Beaulieu, Ph.D. as the head of Regulus microMarkers(TM), a research and development division of Regulus designed to support the expansion of its innovative...

Drug Design From Genome Sequences
2014-02-10 06:22:11

Scripps Research Institute As proof-of-principle, the team designs potent anti-cancer compound In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die. "This is the first time therapeutic small...